Celularity downgraded by Truist with a new price target
$CELU
Biotechnology: Pharmaceutical Preparations
Health Care
Truist downgraded Celularity from Buy to Hold and set a new price target of $10.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/30/2023 | $5.00 → $1.00 | Equal-Weight → Underweight | Morgan Stanley |
| 12/22/2022 | Outperform → Perform | Oppenheimer | |
| 6/22/2022 | $15.00 | Buy | H.C. Wainwright |
| 4/6/2022 | $10.00 | Buy → Hold | Truist |
| 1/28/2022 | $9.00 | Outperform | Oppenheimer |
| 11/24/2021 | $9.00 | Equal-Weight | Morgan Stanley |
| 10/19/2021 | $12.00 | Buy | Truist Securities |
8-K - Celularity Inc (0001752828) (Filer)
8-K - Celularity Inc (0001752828) (Filer)
10-K/A - Celularity Inc (0001752828) (Filer)
4 - Celularity Inc (0001752828) (Issuer)
4 - Celularity Inc (0001752828) (Issuer)
Morgan Stanley downgraded Celularity from Equal-Weight to Underweight and set a new price target of $1.00 from $5.00 previously
Oppenheimer downgraded Celularity from Outperform to Perform
H.C. Wainwright initiated coverage of Celularity with a rating of Buy and set a new price target of $15.00
FLORHAM PARK, N.J., June 10, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a regenerative and cellular medicine company, today announced that it terminated the employment of its Chief Financial Officer ("CFO"), David Beers, effective immediately. Mr. Beer's termination was not related to the Company's financial or operating results or to any disagreements or concerns regarding the Company's financial or reporting practices. Mr. Beers was terminated "without cause" under the terms of his employment agreement dated April 1, 2022, as amended and restated, and, subject to his compliance with its terms, Mr. Beers will be entitled to the payments and ben
Highlights the unique potential of Celularity's proprietary advanced biomaterial technology as a novel cellular delivery system for ocular surface reconstructionSupports broad range of regenerative medicine applications beyond ophthalmology FLORHAM PARK, N.J., June 02, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a regenerative and cellular medicine company, today announced its research published in the May 29, 2025, issue of the peer-reviewed journal Regenerative Engineering and Translational Medicine, a leading open-access journal publishing cutting-edge advances in regenerative medicine. The full study titled "Tri-Layer Decellularized, Dehydr
FLORHAM PARK, N.J., May 30, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a cellular and regenerative medicine company, today announced that on May 28, 2025, Nasdaq notified the Company that it did not timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2025. Based on this latest notice, the Company is not in compliance with Listing Rule 5250 (c)(1), which requires the Company to timely file all required periodic financial reports with the Securities and Exchange Commission. The Notice received from Nasdaq has no immediate effect on the listing or trading of the Company's shares. Nasdaq has provided the Company 60 ca
4/A - Celularity Inc (0001752828) (Issuer)
4 - Celularity Inc (0001752828) (Issuer)
4 - Celularity Inc (0001752828) (Issuer)
FLORHAM PARK, N.J., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) (the "Company"), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today the appointment of Richard J. Berman, to its Board of Directors. Mr. Berman is an experienced public company director whose career spans over 40 years of venture capital, senior management, and merger and acquisitions experience. He has served as a director and/or officer of over a dozen public and private companies in the last five years, six of which have reached over one billion dollars in market value. Previously, Mr. Berman worked at Gol
FLORHAM PARK, N.J., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) (Celularity), a biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies and advanced biomaterial products, today announced the appointment of Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors. Dr. Ling, a distinguished academic and military physician-scientist with a strong background in regenerative medicine and a deep commitment to advancing healthcare, will bring invaluable expertise and insights to Celularity as it continues to pioneer innovative therapies for patients in need. Throughout his career, Dr. Ling has made significant contributions to regenera
FLORHAM PARK, N.J., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a biotechnology company developing placental-derived allogeneic cell and biomaterial therapies, today announced that Paul Graves has been appointed Senior Vice President, Chief Communications Officer, effective January 2, 2023. Mr. Graves is a seasoned communications professional who brings more than 30 years of strategic communications experience in the biopharmaceutical industry. He has deep expertise in corporate reputation, global research and development, product launch and promotion, investor relations and public affairs. He will provide senior strategic communications leadership for C
FLORHAM PARK, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative and cellular medicine company, has issued a Corporate Update to Shareholders from Robert J. Hariri, M.D., Ph.D., Founder, Chairman, and CEO. Dear Shareholders, I am pleased to share recent developments at Celularity, including an update on our commercial-stage advanced biomaterial products business. Let me start by reiterating what we said in our announcement last week, which is that we are resolutely committed to regaining full compliance with Nasdaq's listing requirements. We acknowledge the importance of timely filings and have been diligently working with our new auditi
SC 13D/A - Celularity Inc (0001752828) (Subject)
SC 13G/A - Celularity Inc (0001752828) (Subject)
SC 13D/A - Celularity Inc (0001752828) (Subject)